Advertisement

Topics

FDA To Rule On Elagolix In Q2, More Light From CELG's RADIANCE, TGTX On Watch

23:00 EDT 29 Oct 2017 | RTTNews

Today's Daily Dose brings you news about Neurocrine Biosciences' upcoming regulatory catalyst; Celgene's RADIANCE Part B trial results; tentative approval of Eagle Pharma's cancer drug Pemfexy; trial results of Kura's preclinical drug candidate, KO-539, and phase II drug candidate Tipifarnib.

Original Article: FDA To Rule On Elagolix In Q2, More Light From CELG's RADIANCE, TGTX On Watch

NEXT ARTICLE

More From BioPortfolio on "FDA To Rule On Elagolix In Q2, More Light From CELG's RADIANCE, TGTX On Watch"

Quick Search
Advertisement
 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...